{"id":"W4281638764","doi":"10.1200/jco.2022.40.16_suppl.4537","title":"Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Refractory (planetary science); Population; Immunotherapy; Pembrolizumab; Unison; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002119241,0.0003783916,0.0004720406,0.0001737713,0.0002673564,0.0004276646,0.0003890277,0.0003708065,0.002580643],"category_scores_gemma":[0.0009872458,0.0001844907,0.0006918421,0.000174431,0.000173122,0.0002403338,0.0003582742,0.0005141275,0.0003824837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001016509,"about_ca_system_score_gemma":0.00191057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002560708,"about_ca_topic_score_gemma":0.007991653,"domain_scores_codex":[0.9994625,0.0002977885,0.0000500411,0.00007557343,0.00005917091,0.00005481503],"domain_scores_gemma":[0.9994804,0.00008968361,0.0001348777,0.0000376963,0.00005851004,0.0001987895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2800075,0.01744328,0.1413522,0.003152291,0.002985182,0.0009732184,0.0005302819,0.001505345,0.02038977,0.0008660682,0.02779532,0.5029995],"study_design_scores_gemma":[0.114952,0.449596,0.355455,0.000723012,0.00347077,0.002292235,0.0003755835,0.002244919,0.01393693,0.0003699102,0.05652108,0.00006259307],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837842,0.007561689,0.0005684149,0.0008996404,0.0002498509,0.001911244,0.001205755,0.0000638432,0.003755363],"genre_scores_gemma":[0.98631,0.003839762,0.001923779,0.0009150614,0.0001860357,0.001396939,0.002310859,0.0000152507,0.003102259],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002580643,"threshold_uncertainty_score":0.01120776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05626813755170419,"score_gpt":0.3667935187360519,"score_spread":0.3105253811843477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}